Oxford Biomedica plc (LON:OXB – Get Free Report) insider Heather Preston bought 11,389 shares of the firm’s stock in a transaction on Tuesday, June 17th. The stock was purchased at an average cost of GBX 324 ($4.35) per share, for a total transaction of £36,900.36 ($49,517.39).
Oxford Biomedica Price Performance
OXB stock opened at GBX 314 ($4.21) on Thursday. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. Oxford Biomedica plc has a 12 month low of GBX 232.50 ($3.12) and a 12 month high of GBX 455 ($6.11). The firm has a market cap of £333.79 million, a P/E ratio of -2.33 and a beta of 1.09. The company’s 50-day moving average price is GBX 307.60 and its two-hundred day moving average price is GBX 347.28.
Oxford Biomedica (LON:OXB – Get Free Report) last released its earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.56)) EPS for the quarter. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%. On average, analysts anticipate that Oxford Biomedica plc will post -31.0799998 earnings per share for the current fiscal year.
Oxford Biomedica Company Profile
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
See Also
- Five stocks we like better than Oxford Biomedica
- How to Calculate Inflation Rate
- Chime’s Smart IPO: Half the Valuation, Double the Strength
- How to Short Nasdaq: An Easy-to-Follow Guide
- Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
- What is the Nasdaq? Complete Overview with History
- 3 Catalysts in 7 Days: Archer’s Growth Story Just Accelerated
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.